MedPath

Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder

Phase 2
Recruiting
Conditions
Alcohol Use Disorder
Interventions
Drug: Placebo to match sunobinop
Registration Number
NCT06545916
Lead Sponsor
Imbrium Therapeutics
Brief Summary

The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol consumption in subjects with alcohol use disorder.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo to match sunobinopPlacebo to match sunobinop-
SunobinopSunobinop-
Primary Outcome Measures
NameTimeMethod
Percent heavy drinking days (HDD)Day 57
Secondary Outcome Measures
NameTimeMethod
Number of standard unit drinksDay 57
Percent of drinking days (PDD)Day 57

Trial Locations

Locations (6)

Inquest Clinical Research

🇺🇸

Baytown, Texas, United States

Bio Terra Med SRL

🇷🇴

Bucharest, Romania

Spitalul Universitar De Urgenta Militar Central "Dr. Carol Davila"

🇷🇴

Bucharest, Romania

Cabinet Medical Individual Dr. Andreea Popa

🇷🇴

Bucharest, Romania

Belmont Medical Office

🇺🇸

Brooklyn, New York, United States

Cebis Usa, Llc

🇺🇸

Houston, Texas, United States

Inquest Clinical Research
🇺🇸Baytown, Texas, United States
Central Contact
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.